Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Blood (2024) 144 (24): 2490–2502.

https://doi.org/10.1182/blood.2024024381

Published: 2024

Includes: Supplemental data

Journal Articles

In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript

Blood (2024) 144 (Supplement 1): 7159.

https://doi.org/10.1182/blood-2024-209570

Published: 2024

Journal Articles

Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

Soumya Poddar, Jiali Yan, Gayatri Tiwari, Darawan Rinchai, Wangshu Zhang, Justin Budka, Weixin Peng, Shruti Salunkhe, Madison Davis, Qinghua Song, Sara Beygi, Harry Miao, Mike Mattie, Rhine Shen, Caron A. Jacobson, Davide Bedognetti, Simone Filosto, Sattva S. Neelapu

Blood (2024) 144 (Supplement 1): 4368.

https://doi.org/10.1182/blood-2024-211139

Published: 2024

Journal Articles

Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 2031.

https://doi.org/10.1182/blood-2024-203981

Published: 2024

Journal Articles

Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma

Blood (2024) 144 (Supplement 1): 908.

https://doi.org/10.1182/blood-2024-205905

Published: 2024

Journal Articles

Advancing CAR-T Therapy in Acute Lymphoblastic Leukemia: Multi-Omic Analyses of CD19-Directed CAR-T Cells Enabled By an Ex Vivo Co-Culture Platform

Mike Mattie, Marc Gillard, Monica Calderon, Sophia Do, Shruti Salunkhe, Darren Heeke, Jose Morachis, Benjamin Titz, Chorom Pak

Blood (2023) 142 (Supplement 1): 244.

https://doi.org/10.1182/blood-2023-180395

Published: 2023

Journal Articles

An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma across the Zuma Trials Cohorts

Sandeep Raj, Jin Xie, Teng Fei, Qinghua Song, Jenny J. Kim, Christina To, Marcel R.M. van den Brink, Miguel-Angel Perales, Mike Mattie, Roni Shouval

Blood (2023) 142 (Supplement 1): 224.

https://doi.org/10.1182/blood-2023-173798

Published: 2023

Journal Articles

Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients Undergoing CD19 CAR T Cell Treatment

Dimitra Karagkouni, Xanthi Lida Katopodi, Giulia Cheloni, Yuling Ma, Brodie Miles, Gayatri Tiwari, Jenny J. Kim, Mike Mattie, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos

Blood (2023) 142 (Supplement 1): 1638.

https://doi.org/10.1182/blood-2023-190377

Published: 2023

Journal Articles

Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)

Mike Mattie, Melanie Grosso, Aurelie Auguste, Denis Arnaud, Frederick L. Locke, Sattva S. Neelapu, David B. Miklos, Caron A Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jenny J. Kim, Jenny Nater, Rhine R. Shen, Jerome Galon

Blood (2023) 142 (Supplement 1): 226.

https://doi.org/10.1182/blood-2023-187574

Published: 2023

Journal Articles

Baseline Immune State and T Cell Clonal Kinetics Are Associated with Response to CAR-T Therapy in Large B-Cell Lymphoma

Blood (2023) 142 (Supplement 1): 223.

https://doi.org/10.1182/blood-2023-180819

Published: 2023

Journal Articles

Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site

Ulrike Gerdemann, James Kaminski, Alexandre Albanese, Paula Keskula, Lorenzo Cagnin, Kayla Betz, Jillian Zavistaski, Ryan A Fleming, Caroline Falvey, Riemke Bouvier, Julia Jones, Soumya Poddar, Mike Mattie, Ugonma Chukwueke, Alexandra Torres, Caron A. Jacobson, Lakshmi Nayak, Leslie S. Kean

Blood (2022) 140 (Supplement 1): 408–409.

https://doi.org/10.1182/blood-2022-166645

Published: 2022

Journal Articles

Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial

Carli M. Stewart, Michelle J. Cox, Reona Leo Sakemura, Ekene J. Ogbodo, Ismail Can, Claudia Manriquez-Roman, Kun Yun, Olivia Sirpilla, James H. Girsch, Truc Huynh, Elizabeth L. Siegler, Jenny J Kim, Mike Mattie, Nathalie Scholler, Simone Filosto, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 4536–4537.

https://doi.org/10.1182/blood-2022-160219

Published: 2022

Journal Articles

Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19

Kun Yun, Reona Leo Sakemura, Michelle J. Cox, Truc Huynh, Claudia Manriquez-Roman, Olivia Sirpilla, Carli M. Stewart, James H. Girsch, Ekene J. Ogbodo, Ismail Can, Brooke Kimball, Lionel A. Kankeu Fonkoua, Mehrdad Hefazi, Michael W. Ruff, Elizabeth L. Siegler, Mike Mattie, Sao-Mai Nguyen-Mau, Simone Filosto, Saad S. Kenderian

Blood (2022) 140 (Supplement 1): 10263–10264.

https://doi.org/10.1182/blood-2022-164706

Published: 2022

Journal Articles

Durable Response to CD19 CAR T Cell Therapy Is Associated with Cytotoxicity and Clonotypic Expansion of the Native T Cell Repertoire

Giulia Cheloni, Dimitra Karagkouni, Yered Pita-Juarez, Daniela Torres, Eleni Kanata, Zachary M. Avigan, Jessica Liegel, Dina Stroopinsky, Brodie Miles, Gayatri Tiwari, Jenny Kim, Mike Mattie, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos

Blood (2022) 140 (Supplement 1): 644–645.

https://doi.org/10.1182/blood-2022-169230

Published: 2022

Journal Articles

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Blood (2022) 140 (Supplement 1): 4678–4680.

https://doi.org/10.1182/blood-2022-171084

Published: 2022

Journal Articles

A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)

Blood (2022) 140 (Supplement 1): 1060–1061.

https://doi.org/10.1182/blood-2022-165256

Published: 2022

Journal Articles

Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T

Giulia Cheloni, Eleni Kanata, Dina Stroopinsky, Dimitra Karagkouni, Jessica J. Liegel, Daniela Torres, Joshua Hauser, Poorva Bindal, Anita G. Koshy, Yered Pita-Juarez, Adrian Bot, Mike Mattie, Justin Chou, Jacalyn Rosenblatt, David Avigan, Ioannis Vlachos

Blood (2021) 138 (Supplement 1): 2786.

https://doi.org/10.1182/blood-2021-151459

Published: 2021

Journal Articles

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

Blood (2021) 138 (Supplement 1): 901.

https://doi.org/10.1182/blood-2021-148591

Published: 2021

NARROW

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

In Vitro and In Vivo Characterization of Axicabtagene Ciloleucel Identifies Features Associated with Treatment Resistance in Patients, Including a Dysfunctional CD8+ T Cell State Characterized By Overexpression of GATA3 Transcript

Impact of Inflammation, Tumor and Product Attributes on Clinical Outcomes in Patients with Relapsed/Refractory Follicular Lymphoma Treated with Axicabtagene Ciloleucel

Early MRD Detection after CAR-T Associated with Poor Outcome in Patients with Large B-Cell Lymphoma

Intrinsic Immunosuppressive Features of Monocytes Suppress CART19 through IL-1 Pathway Modulation in Mantle Cell Lymphoma

Advancing CAR-T Therapy in Acute Lymphoblastic Leukemia: Multi-Omic Analyses of CD19-Directed CAR-T Cells Enabled By an Ex Vivo Co-Culture Platform

An Inflammatory Biomarker Signature Reproducibly Predicts CAR-T Treatment Failure in Patients with Aggressive Lymphoma across the Zuma Trials Cohorts

Personal and Shared Tumor-Antigen Prioritization in Diffuse Large B Cell Lymphoma Patients Undergoing CD19 CAR T Cell Treatment

Pre- and Post-Treatment Immune Contexture Correlates with Long Term Response in Large B Cell Lymphoma Patients Treated with Axicabtagene Ciloleucel (axi-cel)

Baseline Immune State and T Cell Clonal Kinetics Are Associated with Response to CAR-T Therapy in Large B-Cell Lymphoma

Targeting CNS Lymphoma with Intravenous Axicabtagene Ciloleucel: Evidence for Transcriptional Evolution Towards a Prominent Interferon Signature in CAR-T Cells Trafficking to the Tumor Site

Identification of IL-4 As a Key Regulator of CAR T-Cell Exhaustion Using Functional Genomics and Correlates of the Zuma-1 Clinical Trial

Immunosuppressive Monocyte Modulation of CAR T Cell Functions and Impact on Response to CART19

Durable Response to CD19 CAR T Cell Therapy Is Associated with Cytotoxicity and Clonotypic Expansion of the Native T Cell Repertoire

Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

A Pilot Study of Axicabtagene Ciloleucel (axi-cel) for the Treatment of Relapsed/Refractory Primary and Secondary Central Nervous System Lymphoma (CNSL)

Profiling the Peripheral Blood Immune Cell Repertoire in Large-B Cell Lymphoma Patients Treated with CD19 CAR-T

TNFR2 As a Target to Improve CD19-Directed CART Cell Fitness and Antitumor Activity in Large B Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only